2015 Q4 Form 10-Q Financial Statement
#000162828015008436 Filed on November 06, 2015
Income Statement
| Concept | 2015 Q4 | 2015 Q3 | 2014 Q4 |
|---|---|---|---|
| Revenue | $30.45M | $28.01M | $14.09M |
| YoY Change | 116.17% | 235.47% | |
| Cost Of Revenue | $760.0K | $513.0K | $340.0K |
| YoY Change | 123.53% | 159.09% | |
| Gross Profit | $29.69M | $27.49M | $13.75M |
| YoY Change | 115.93% | 237.33% | |
| Gross Profit Margin | 97.51% | 98.17% | 97.62% |
| Selling, General & Admin | $18.95M | $22.31M | $18.46M |
| YoY Change | 2.65% | 28.41% | 152.88% |
| % of Gross Profit | 63.83% | 81.14% | 134.25% |
| Research & Development | $15.37M | $14.06M | $14.19M |
| YoY Change | 8.32% | 11.21% | 185.51% |
| % of Gross Profit | 51.77% | 51.16% | 103.2% |
| Depreciation & Amortization | $3.970M | $3.880M | $1.860M |
| YoY Change | 113.44% | 109.73% | 3000.0% |
| % of Gross Profit | 13.37% | 14.11% | 13.53% |
| Operating Expenses | $45.65M | $48.50M | $32.78M |
| YoY Change | 39.26% | 60.52% | 176.12% |
| Operating Profit | -$15.20M | -$20.50M | -$18.70M |
| YoY Change | -18.68% | -6.27% | 57.49% |
| Interest Expense | -$4.210M | -$695.0K | -$10.33M |
| YoY Change | -59.24% | -73.56% | 549.69% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $2.210M | $164.8M | -$10.33M |
| YoY Change | -121.39% | 4140.67% | 1081.52% |
| Pretax Income | -$12.99M | $144.3M | -$29.03M |
| YoY Change | -55.23% | -902.78% | 127.73% |
| Income Tax | -$10.53M | $38.76M | $0.00 |
| % Of Pretax Income | 26.85% | ||
| Net Earnings | -$2.469M | $105.6M | -$29.03M |
| YoY Change | -91.49% | -687.2% | 126.38% |
| Net Earnings / Revenue | -8.11% | 377.0% | -206.08% |
| Basic Earnings Per Share | -$0.07 | $2.95 | -$1.10 |
| Diluted Earnings Per Share | -$0.14 | $1.78 | -$1.10 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 36.15M shares | 35.74M shares | |
| Diluted Shares Outstanding | 42.75M shares |
Balance Sheet
| Concept | 2015 Q4 | 2015 Q3 | 2014 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $229.6M | $235.3M | $27.76M |
| YoY Change | 727.1% | 522.43% | 355.08% |
| Cash & Equivalents | $37.81M | $140.6M | $18.20M |
| Short-Term Investments | $191.8M | $94.68M | $9.556M |
| Other Short-Term Assets | $10.50M | $2.000M | $800.0K |
| YoY Change | 1212.5% | -13.04% | -42.86% |
| Inventory | $2.536M | $2.650M | $801.0K |
| Prepaid Expenses | |||
| Receivables | $12.46M | $13.50M | $7.960M |
| Other Receivables | $46.80M | $46.50M | $0.00 |
| Total Short-Term Assets | $301.9M | $300.0M | $37.33M |
| YoY Change | 708.73% | 560.69% | 397.7% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $428.0K | $478.0K | $671.0K |
| YoY Change | -36.21% | -20.33% | 426.58% |
| Goodwill | $936.0K | $936.0K | $936.0K |
| YoY Change | 0.0% | ||
| Intangibles | $161.5M | ||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $1.859M | $2.006M | $2.265M |
| YoY Change | -17.92% | -12.78% | 655.0% |
| Total Long-Term Assets | $210.3M | $211.7M | $98.14M |
| YoY Change | 114.32% | 110.62% | 655.04% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $301.9M | $300.0M | $37.33M |
| Total Long-Term Assets | $210.3M | $211.7M | $98.14M |
| Total Assets | $512.3M | $511.6M | $135.5M |
| YoY Change | 278.14% | 250.67% | 560.87% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $7.639M | $4.893M | $7.124M |
| YoY Change | 7.23% | -56.7% | 100.47% |
| Accrued Expenses | $23.82M | $22.32M | $27.88M |
| YoY Change | -14.57% | 90.75% | 471.21% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $40.50M |
| YoY Change | -100.0% | ||
| Long-Term Debt Due | $1.000M | $1.000M | |
| YoY Change | -33.33% | -37.5% | |
| Total Short-Term Liabilities | $86.98M | $101.9M | $107.5M |
| YoY Change | -19.12% | 107.63% | 194.1% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $43.80M | $43.70M | $43.30M |
| YoY Change | 1.15% | 1.39% | |
| Other Long-Term Liabilities | $3.066M | $13.92M | $1.617M |
| YoY Change | 89.61% | -78.16% | 61.7% |
| Total Long-Term Liabilities | $3.066M | $13.92M | $1.617M |
| YoY Change | 89.61% | -86.97% | 61.7% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $86.98M | $101.9M | $107.5M |
| Total Long-Term Liabilities | $3.066M | $13.92M | $1.617M |
| Total Liabilities | $212.3M | $220.6M | $172.7M |
| YoY Change | 22.91% | 41.33% | 330.02% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$65.15M | -$62.68M | -$179.2M |
| YoY Change | -63.64% | 162.58% | |
| Common Stock | $365.8M | $353.8M | $140.9M |
| YoY Change | 159.71% | 7593107.55% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $0.00 | $0.00 | $3.215M |
| YoY Change | -100.0% | 235.85% | |
| Treasury Stock Shares | 0.000 shares | 0.000 shares | 379.6K shares |
| Shareholders Equity | $300.0M | $291.0M | -$37.25M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $512.3M | $511.6M | $135.5M |
| YoY Change | 278.14% | 250.67% | 560.87% |
Cashflow Statement
| Concept | 2015 Q4 | 2015 Q3 | 2014 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$2.469M | $105.6M | -$29.03M |
| YoY Change | -91.49% | -687.2% | 126.38% |
| Depreciation, Depletion And Amortization | $3.970M | $3.880M | $1.860M |
| YoY Change | 113.44% | 109.73% | 3000.0% |
| Cash From Operating Activities | -$3.550M | $1.590M | -$9.090M |
| YoY Change | -60.95% | -110.26% | 11.53% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$1.720M | -$3.880M | -$80.00K |
| YoY Change | 2050.0% | 2486.67% | -33.33% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$98.74M | $55.01M | $2.050M |
| YoY Change | -4916.59% | -2995.26% | 48.55% |
| Cash From Investing Activities | -$100.5M | $51.12M | $1.970M |
| YoY Change | -5199.49% | -2581.55% | 56.35% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.230M | -39.87M | -530.0K |
| YoY Change | -332.08% | -1226.27% | 0.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -3.550M | 1.590M | -9.090M |
| Cash From Investing Activities | -100.5M | 51.12M | 1.970M |
| Cash From Financing Activities | 1.230M | -39.87M | -530.0K |
| Net Change In Cash | -102.8M | 12.84M | -7.650M |
| YoY Change | 1243.53% | -191.58% | 3.1% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$3.550M | $1.590M | -$9.090M |
| Capital Expenditures | -$1.720M | -$3.880M | -$80.00K |
| Free Cash Flow | -$1.830M | $5.470M | -$9.010M |
| YoY Change | -79.69% | -135.64% | 12.2% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2015 | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2015-09-30 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001438533 | ||
| CY2015Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
36148930 | shares |
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| CY2015Q3 | dei |
Entity Number Of Employees
EntityNumberOfEmployees
|
126 | Employee |
| dei |
Entity Registrant Name
EntityRegistrantName
|
Retrophin, Inc. | ||
| dei |
Trading Symbol
TradingSymbol
|
rtrx | ||
| CY2014Q4 | rtrx |
Accrued Liabilities License Fees Current
AccruedLiabilitiesLicenseFeesCurrent
|
3000000 | USD |
| CY2015Q3 | rtrx |
Accrued Liabilities License Fees Current
AccruedLiabilitiesLicenseFeesCurrent
|
0 | USD |
| CY2014Q4 | rtrx |
Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
|
3720000 | USD |
| CY2015Q3 | rtrx |
Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
|
2222000 | USD |
| CY2014Q4 | rtrx |
Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
|
2411000 | USD |
| CY2015Q3 | rtrx |
Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
|
1807000 | USD |
| rtrx |
Accrued Royalty In Excess Of Minimum Payable To Sellers
AccruedRoyaltyInExcessOfMinimumPayableToSellers
|
0 | USD | |
| rtrx |
Accrued Royalty In Excess Of Minimum Payable To Sellers
AccruedRoyaltyInExcessOfMinimumPayableToSellers
|
2237000 | USD | |
| CY2014Q4 | rtrx |
Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
|
2118000 | USD |
| CY2015Q3 | rtrx |
Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
|
5069000 | USD |
| CY2014Q4 | rtrx |
Acquisition Related Contingent Consideration Noncurrent
AcquisitionRelatedContingentConsiderationNoncurrent
|
9520000 | USD |
| CY2015Q3 | rtrx |
Acquisition Related Contingent Consideration Noncurrent
AcquisitionRelatedContingentConsiderationNoncurrent
|
48651000 | USD |
| CY2014Q3 | rtrx |
Bargain Purchase Gain
BargainPurchaseGain
|
0 | USD |
| rtrx |
Bargain Purchase Gain
BargainPurchaseGain
|
0 | USD | |
| CY2015Q3 | rtrx |
Bargain Purchase Gain
BargainPurchaseGain
|
0 | USD |
| rtrx |
Bargain Purchase Gain
BargainPurchaseGain
|
49063000 | USD | |
| CY2014Q3 | rtrx |
Change In Fair Value Of Derivative Instruments
ChangeInFairValueOfDerivativeInstruments
|
0 | USD |
| CY2015Q3 | rtrx |
Change In Fair Value Of Derivative Instruments
ChangeInFairValueOfDerivativeInstruments
|
0 | USD |
| rtrx |
Payment Of Acquisition Related Contingent Consideration
PaymentOfAcquisitionRelatedContingentConsideration
|
2498000 | USD | |
| rtrx |
Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
|
0 | USD | |
| rtrx |
Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
|
527000 | USD | |
| rtrx |
Paymentof Other Liability
PaymentofOtherLiability
|
507000 | USD | |
| CY2014Q4 | rtrx |
Government Rebates Payable
GovernmentRebatesPayable
|
1353000 | USD |
| rtrx |
Paymentof Other Liability
PaymentofOtherLiability
|
1000000 | USD | |
| CY2015Q3 | rtrx |
Early Payment Penalty
EarlyPaymentPenalty
|
0 | USD |
| rtrx |
Cover Securities Sold Not Yet Purchased
CoverSecuritiesSoldNotYetPurchased
|
-5310000 | USD | |
| rtrx |
Cover Securities Sold Not Yet Purchased
CoverSecuritiesSoldNotYetPurchased
|
0 | USD | |
| rtrx |
Derivative Financial Instruments Warrants Issued Recorded In Interest Expense
DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense
|
0 | USD | |
| rtrx |
Derivative Financial Instruments Warrants Issued Recorded In Interest Expense
DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense
|
1050000 | USD | |
| CY2014Q3 | rtrx |
Early Payment Penalty
EarlyPaymentPenalty
|
0 | USD |
| rtrx |
Early Payment Penalty
EarlyPaymentPenalty
|
0 | USD | |
| rtrx |
Early Payment Penalty
EarlyPaymentPenalty
|
2250000 | USD | |
| CY2014Q3 | rtrx |
Finance Expense
FinanceExpense
|
13000 | USD |
| CY2014Q3 | rtrx |
Change In Fair Value Of Derivative Instruments In Shares
ChangeInFairValueOfDerivativeInstrumentsInShares
|
1527715 | shares |
| CY2015Q3 | rtrx |
Change In Fair Value Of Derivative Instruments In Shares
ChangeInFairValueOfDerivativeInstrumentsInShares
|
2053934 | shares |
| CY2015Q3 | rtrx |
Contractual Obligation Due In Rolling After Year Five
ContractualObligationDueInRollingAfterYearFive
|
1492000 | USD |
| CY2015Q3 | rtrx |
Contractual Obligation Due In Rolling Year Four And Five
ContractualObligationDueInRollingYearFourAndFive
|
870000 | USD |
| CY2015Q3 | rtrx |
Contractual Obligation Due In Rolling Year Two And Three
ContractualObligationDueInRollingYearTwoAndThree
|
2187000 | USD |
| CY2015Q3 | rtrx |
Contractual Obligation Next Rolling Twelve Months
ContractualObligationNextRollingTwelveMonths
|
1826000 | USD |
| rtrx |
Finance Expense
FinanceExpense
|
4721000 | USD | |
| CY2015Q3 | rtrx |
Finance Expense
FinanceExpense
|
0 | USD |
| rtrx |
Finance Expense
FinanceExpense
|
600000 | USD | |
| rtrx |
Gain Loss Upon Divestiture Of Assets
GainLossUponDivestitureOfAssets
|
0 | USD | |
| rtrx |
Gain Loss Upon Divestiture Of Assets
GainLossUponDivestitureOfAssets
|
140004000 | USD | |
| rtrx |
Gain Loss Upon Divestiture Of Assetsto Company
GainLossUponDivestitureOfAssetstoCompany
|
200000 | USD | |
| CY2015Q3 | rtrx |
Proceeds From Issuance Of Warrants One
ProceedsFromIssuanceOfWarrantsOne
|
3800000 | USD |
| CY2015Q3 | rtrx |
Government Rebates Payable
GovernmentRebatesPayable
|
5226000 | USD |
| rtrx |
Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
|
0 | USD | |
| rtrx |
Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
|
-32000 | USD | |
| CY2014Q3 | rtrx |
Increase Decrease In Net Income Loss
IncreaseDecreaseInNetIncomeLoss
|
1600000 | USD |
| rtrx |
Increase Decrease In Net Income Loss
IncreaseDecreaseInNetIncomeLoss
|
-200000 | USD | |
| rtrx |
Increase Decrease In Settlement Expense
IncreaseDecreaseInSettlementExpense
|
-5684000 | USD | |
| rtrx |
Increase Decrease In Settlement Expense
IncreaseDecreaseInSettlementExpense
|
0 | USD | |
| rtrx |
Note Payable Entered Into Upon Consummation Of An Entity
NotePayableEnteredIntoUponConsummationOfAnEntity
|
31283000 | USD | |
| rtrx |
Note Payable Entered Into Upon Consummation Of An Entity
NotePayableEnteredIntoUponConsummationOfAnEntity
|
0 | USD | |
| CY2015Q3 | rtrx |
Other Commitments Due In Rolling After Year Five
OtherCommitmentsDueInRollingAfterYearFive
|
1492000 | USD |
| CY2015Q3 | rtrx |
Other Commitments Due In Rolling Year Four And Five
OtherCommitmentsDueInRollingYearFourAndFive
|
870000 | USD |
| CY2015Q3 | rtrx |
Other Commitments Due In Rolling Year Two And Three
OtherCommitmentsDueInRollingYearTwoAndThree
|
1133000 | USD |
| CY2015Q3 | rtrx |
Other Commitments Next Rolling Twelve Months
OtherCommitmentsNextRollingTwelveMonths
|
1029000 | USD |
| rtrx |
Payment Of Acquisition Related Contingent Consideration
PaymentOfAcquisitionRelatedContingentConsideration
|
562000 | USD | |
| rtrx |
Paymentsto Security Deposits
PaymentstoSecurityDeposits
|
93000 | USD | |
| rtrx |
Paymentsto Security Deposits
PaymentstoSecurityDeposits
|
0 | USD | |
| rtrx |
Present Value Of Contingent Consideration Payable To Sellers
PresentValueOfContingentConsiderationPayableToSellers
|
12238000 | USD | |
| rtrx |
Present Value Of Contingent Consideration Payable To Sellers
PresentValueOfContingentConsiderationPayableToSellers
|
0 | USD | |
| rtrx |
Present Value Of Guaranteed Minimum Royalty Payable To Sellers Of An Entity
PresentValueOfGuaranteedMinimumRoyaltyPayableToSellersOfAnEntity
|
11818000 | USD | |
| rtrx |
Present Value Of Guaranteed Minimum Royalty Payable To Sellers Of An Entity
PresentValueOfGuaranteedMinimumRoyaltyPayableToSellersOfAnEntity
|
0 | USD | |
| rtrx |
Proceeds From Issuance Of Warrants One
ProceedsFromIssuanceOfWarrantsOne
|
4300000 | USD | |
| rtrx |
Reclassification Of Derivative Liability To Equity
ReclassificationOfDerivativeLiabilityToEquity
|
23365000 | USD | |
| rtrx |
Reclassification Of Derivative Liability To Equity
ReclassificationOfDerivativeLiabilityToEquity
|
23100000 | USD | |
| CY2015Q3 | rtrx |
Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
|
19100000 | USD |
| rtrx |
Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
|
23100000 | USD | |
| rtrx |
Shares Issued Related To Acquisition
SharesIssuedRelatedToAcquisition
|
0 | USD | |
| rtrx |
Shares Issued Related To Acquisition
SharesIssuedRelatedToAcquisition
|
15844000 | USD | |
| CY2015Q3 | rtrx |
Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
|
630557 | shares |
| rtrx |
Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
|
818610 | shares | |
| CY2014Q4 | rtrx |
Technology License Liability Current
TechnologyLicenseLiabilityCurrent
|
1000000 | USD |
| CY2015Q3 | rtrx |
Technology License Liability Current
TechnologyLicenseLiabilityCurrent
|
1000000 | USD |
| CY2015Q1 | rtrx |
Underwriting Fees And Other Offering Costs
UnderwritingFeesAndOtherOfferingCosts
|
9500000 | USD |
| rtrx |
Unrealized Gain On Securities Sold Not Yet Purchased
UnrealizedGainOnSecuritiesSoldNotYetPurchased
|
34000 | USD | |
| rtrx |
Unrealized Gain On Securities Sold Not Yet Purchased
UnrealizedGainOnSecuritiesSoldNotYetPurchased
|
0 | USD | |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
7124000 | USD |
| CY2015Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4893000 | USD |
| CY2014Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
7960000 | USD |
| CY2015Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
13499000 | USD |
| CY2014Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
5710000 | USD |
| CY2015Q3 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
1548000 | USD |
| CY2014Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
27883000 | USD |
| CY2015Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1186000 | USD |
| CY2015Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
22318000 | USD |
| CY2014Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1208000 | USD |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3543000 | USD | |
| CY2015Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
353794000 | USD |
| CY2014Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3204000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9237000 | USD | |
| CY2015Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8181000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
18748000 | USD | |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
571000 | USD | |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
1175000 | USD | |
| CY2014Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1815000 | USD |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
3467000 | USD | |
| CY2015Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
3875000 | USD |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9417000 | USD | |
| CY2014Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6270576 | shares |
| CY2014Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
0 | USD |
| CY2015Q3 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
4249000 | USD |
| CY2014Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
8163000 | USD |
| CY2015Q3 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
5094000 | USD |
| CY2014Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
4285000 | USD |
| CY2015Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-102000 | USD |
| CY2014Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
140851000 | USD |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6763507 | shares | |
| CY2015Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1788924 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3815814 | shares | |
| CY2014Q4 | us-gaap |
Assets
Assets
|
135471000 | USD |
| CY2015Q3 | us-gaap |
Assets
Assets
|
511630000 | USD |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
37334000 | USD |
| CY2015Q3 | us-gaap |
Assets Current
AssetsCurrent
|
299954000 | USD |
| CY2014Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
9556000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
94681000 | USD |
| CY2014Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
4499000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
20000 | USD |
| CY2014Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
103000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
132000 | USD |
| CY2014Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
5160000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
94793000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
0 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
|
132000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
|
77424000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
132000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
77424000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
|
0 | USD |
| CY2014Q4 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
9556000 | USD |
| CY2015Q3 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
94681000 | USD |
| us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
544000 | USD | |
| us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
-293000 | USD | |
| CY2014Q3 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | USD |
| CY2014Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
25862000 | USD |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
18204000 | USD |
| CY2015Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
140596000 | USD |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
9417000 | USD | |
| us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | USD | |
| CY2015Q3 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
6906000 | USD |
| us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
7026000 | USD | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5997000 | USD |
| us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.029 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
19865000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
122392000 | USD | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
115319000 | USD | |
| CY2015Q3 | us-gaap |
Contractual Obligation
ContractualObligation
|
6375000 | USD |
| CY2015Q3 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
12358000 | USD |
| CY2014Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3421255 | shares |
| CY2015Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2691589 | shares |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2015Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
26428071 | shares |
| CY2015Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
36008096 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
26048480 | shares |
| CY2015Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
36008096 | shares |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | USD |
| CY2015Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | USD |
| CY2014Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14748000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-78160000 | USD | |
| CY2015Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
104716000 | USD |
| CY2014Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
43288000 | USD |
| CY2015Q3 | us-gaap |
Convertible Debt
ConvertibleDebt
|
43747000 | USD |
| CY2014Q3 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
198000 | USD |
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
233000 | USD | |
| CY2015Q3 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
513000 | USD |
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
1424000 | USD | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | USD | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-11791000 | USD | |
| CY2014Q4 | us-gaap |
Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
|
0 | USD |
| CY2015Q3 | us-gaap |
Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
|
15892000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
141000 | USD |
| CY2014Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
27990000 | USD |
| CY2015Q3 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
42120000 | USD |
| CY2014Q3 | us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
0 | USD |
| us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
0 | USD | |
| CY2015Q3 | us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
518000 | USD |
| us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
1553000 | USD | |
| CY2014Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.67 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.25 | ||
| CY2015Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
2.95 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
3.67 | ||
| CY2014Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.84 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.25 | ||
| CY2015Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.78 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
3.30 | ||
| CY2014Q3 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-852000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4676000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
5540000 | USD | |
| us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
0 | USD | |
| CY2015Q3 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.269 | |
| us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.011 | ||
| CY2014Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-6359000 | USD |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
14276000 | USD | |
| CY2015Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-29991000 | USD |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
36180000 | USD | |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
5602000 | USD |
| CY2015Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
13752000 | USD |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
99867000 | USD |
| CY2015Q3 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
176749000 | USD |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
94265000 | USD |
| CY2015Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
162997000 | USD |
| CY2014Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
0 | USD |
| us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
0 | USD | |
| CY2015Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
14000 | USD |
| us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
8000 | USD | |
| CY2014Q3 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | USD |
| us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | USD | |
| us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
9628000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
165000 | USD | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-1246000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
13764000 | USD | |
| CY2015Q3 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
140004000 | USD |
| us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
140004000 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-112000 | USD | |
| CY2014Q3 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
0 | USD |
| us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
0 | USD | |
| CY2015Q3 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
0 | USD |
| us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
15500000 | USD | |
| CY2014Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | USD |
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | USD | |
| CY2015Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-4151000 | USD |
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-4151000 | USD | |
| CY2014Q4 | us-gaap |
Goodwill
Goodwill
|
936000 | USD |
| CY2015Q3 | us-gaap |
Goodwill
Goodwill
|
936000 | USD |
| CY2014Q3 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | USD |
| us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | USD | |
| CY2015Q3 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
4710000 | USD |
| us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
4710000 | USD | |
| CY2014Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-17980000 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-84371000 | USD | |
| CY2015Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
144339000 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
118460000 | USD | |
| CY2014Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-2460000 | USD | |
| CY2015Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
38761000 | USD |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1071000 | USD | |
| CY2014Q3 | us-gaap |
Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
|
-1600000 | USD |
| us-gaap |
Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
|
200000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1242000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1712000 | USD | |
| CY2014Q3 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares |
| us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares | |
| CY2015Q3 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
2642160 | shares |
| us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
2642160 | shares | |
| CY2014Q3 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-2600000 | USD |
| us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-4800000 | USD | |
| CY2015Q3 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-700000 | USD |
| us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-7400000 | USD | |
| CY2014Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-2629000 | USD |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
1995000 | USD | |
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-4808000 | USD | |
| CY2015Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-695000 | USD |
| CY2014Q4 | us-gaap |
Liabilities
Liabilities
|
172722000 | USD |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-39233000 | USD | |
| CY2015Q3 | us-gaap |
Liabilities
Liabilities
|
220618000 | USD |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
19859000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-36755000 | USD | |
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-7415000 | USD | |
| us-gaap |
Interest Paid
InterestPaid
|
3114000 | USD | |
| us-gaap |
Interest Paid
InterestPaid
|
4994000 | USD | |
| CY2014Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
2318000 | USD |
| CY2015Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
799000 | USD |
| CY2014Q4 | us-gaap |
Inventory Net
InventoryNet
|
801000 | USD |
| CY2015Q3 | us-gaap |
Inventory Net
InventoryNet
|
2650000 | USD |
| us-gaap |
Investment Sold Not Yet Purchased Sale Proceeds
InvestmentSoldNotYetPurchasedSaleProceeds
|
7500000 | USD | |
| us-gaap |
Investment Sold Not Yet Purchased Sale Proceeds
InvestmentSoldNotYetPurchasedSaleProceeds
|
0 | USD | |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
135471000 | USD |
| CY2015Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
511630000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
107539000 | USD |
| CY2015Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
101947000 | USD |
| CY2015Q3 | us-gaap |
Long Term Debt
LongTermDebt
|
46000000 | USD |
| CY2015Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
|
0 | USD |
| CY2015Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
|
46000000 | USD |
| CY2015Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
0 | USD |
| CY2015Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
0 | USD |
| CY2015Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
0 | USD |
| CY2015Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
|
0 | USD |
| CY2014Q4 | us-gaap |
Marketable Securities
MarketableSecurities
|
9556000 | USD |
| CY2015Q3 | us-gaap |
Marketable Securities
MarketableSecurities
|
94681000 | USD |
| us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
3701000 | USD | |
| us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-4395000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
95853000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
100538000 | USD | |
| CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17980000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-81911000 | USD | |
| CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
105578000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
119706000 | USD | |
| CY2014Q3 | us-gaap |
Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
|
-23669000 | USD |
| us-gaap |
Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
|
-81911000 | USD | |
| CY2015Q3 | us-gaap |
Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
|
76105000 | USD |
| us-gaap |
Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
|
121259000 | USD | |
| CY2014Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3887000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-23260000 | USD | |
| CY2015Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
164835000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
154006000 | USD | |
| CY2014Q4 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
0 | USD |
| CY2015Q3 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
46526000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
104990000 | USD | |
| CY2014Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-21867000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-61111000 | USD | |
| CY2015Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-20496000 | USD |
| CY2015Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1027000 | USD |
| CY2014Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
12234000 | USD |
| CY2015Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
13915000 | USD |
| us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
4708000 | USD | |
| CY2014Q4 | us-gaap |
Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
|
0 | USD |
| CY2015Q3 | us-gaap |
Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
|
45259000 | USD |
| CY2014Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
40486000 | USD |
| CY2015Q3 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
0 | USD |
| CY2014Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
30216000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
75229000 | USD | |
| CY2015Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
48501000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-35546000 | USD | |
| CY2015Q3 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
1851000 | USD |
| CY2015Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling After Year Five
OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive
|
0 | USD |
| CY2015Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling Year Four And Five
OperatingLeasesFutureMinimumPaymentsDueInRollingYearFourAndFive
|
0 | USD |
| CY2015Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling Year Two And Three
OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwoAndThree
|
1054000 | USD |
| CY2015Q3 | us-gaap |
Operating Leases Future Minimum Payments Next Rolling Twelve Months
OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths
|
797000 | USD |
| CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
0 | USD |
| CY2015Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
187000 | USD |
| CY2014Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2265000 | USD |
| CY2015Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2006000 | USD |
| CY2015Q3 | us-gaap |
Other Commitment
OtherCommitment
|
4524000 | USD |
| CY2014Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
3232000 | USD |
| us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
3751000 | USD | |
| CY2015Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-876000 | USD |
| us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-4395000 | USD | |
| CY2014Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
938000 | USD |
| us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
0 | USD | |
| CY2014Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
170000 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
545000 | USD | |
| CY2015Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-314000 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
35000 | USD | |
| us-gaap |
Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
|
0 | USD | |
| us-gaap |
Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
|
42010000 | USD | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
2257000 | USD | |
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | USD | |
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
9500000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
10149000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
94793000 | USD | |
| us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
29150000 | USD | |
| us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
33430000 | USD | |
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
3302000 | USD | |
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
5271000 | USD | |
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
400000 | USD | |
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
0 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
581000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
35000 | USD | |
| CY2014Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2015Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2015Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2015Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2015Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2014Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
813000 | USD |
| CY2015Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2002000 | USD |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
140000000 | USD |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
36835000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
149454000 | USD | |
| us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
8337000 | USD | |
| us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
4372000 | USD | |
| us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
42366000 | USD | |
| us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
0 | USD | |
| us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
42924000 | USD | |
| us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
0 | USD | |
| us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
2252000 | USD | |
| us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
4977000 | USD | |
| us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
0 | USD | |
| us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
148411000 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
5237000 | USD | |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
671000 | USD |
| CY2015Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
478000 | USD |
| us-gaap |
Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
|
0 | USD | |
| us-gaap |
Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
|
45000000 | USD | |
| us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
31283000 | USD | |
| us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | USD | |
| CY2014Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12646000 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
32899000 | USD | |
| CY2015Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14064000 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
34974000 | USD | |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-179175000 | USD |
| CY2015Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-62684000 | USD |
| CY2014Q3 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
8349000 | USD |
| us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
14118000 | USD | |
| CY2015Q3 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
28005000 | USD |
| us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
69444000 | USD | |
| CY2014Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
17372000 | USD |
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
42097000 | USD | |
| CY2015Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
22308000 | USD |
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
56856000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9237000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
18748000 | USD | |
| CY2015Q1 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
19.00 | |
| CY2015Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
7866000 | shares |
| CY2015Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
140000000 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-37251000 | USD |
| CY2015Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
291012000 | USD |
| CY2014Q4 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
0 | USD |
| CY2015Q3 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
9628000 | USD |
| CY2014Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
379591 | shares |
| CY2015Q3 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
0 | shares |
| CY2014Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
3215000 | USD |
| CY2015Q3 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
0 | USD |
| CY2014Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | USD |
| CY2015Q3 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
400000 | USD |
| us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
400000 | USD | |
| CY2014Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28210225 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
25229847 | shares | |
| CY2015Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
42752859 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
36800536 | shares | |
| CY2014Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
26682510 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
25229847 | shares | |
| CY2015Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
35741877 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32650408 | shares | |
| us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">BASIS OF PRESENTATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> (the “2014 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 11, 2015, and amended on March 13, 2015. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions to Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods.  The </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> balance sheet information was derived from the audited financial statements as of that date.</font></div></div> | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization and Description of Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In this Quarterly Report on Form 10-Q, unless the context requires otherwise, the terms “we”, “our”, “us”, “Retrophin” and the “Company” refer to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. We are a fully integrated biopharmaceutical company with approximately </font><font style="font-family:inherit;font-size:10pt;">126</font><font style="font-family:inherit;font-size:10pt;"> employees headquartered in San Diego, California focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious, catastrophic or rare diseases and that we believe offer attractive growth characteristics.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently sell the following three products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chenodal</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (chenodeoxycholic acid) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> has been the standard of care for cerebrotendinous xanthomatosis (“CTX”) patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thiola</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (tiopronin) is approved in the United States for the prevention of cysteine (kidney) stone formation in patients with cystinuria.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cholbam</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (cholic acid) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sparsentan</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">,</font><font style="font-family:inherit;font-size:10pt;"> also known as RE-021, is an investigational therapeutic agent which acts as both a potent angiotensin receptor blocker (“ARB”), as well as a selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. We are developing sparsentan as a treatment for focal segmental glomerulosclerosis (“FSGS”), which is a leading cause of end-stage renal disease. We are currently enrolling patients for the DUET Phase 2 clinical study of sparsentan for the treatment of FSGS. Based on the robustness of the data obtained in the DUET study, we may be able to support an application for accelerated approval for sparsentan on the basis of proteinuria as a surrogate endpoint. In the first quarter of 2015, sparsentan received orphan drug designation from the U.S. Food and Drug Administration (“FDA”).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RE-024, a novel small molecule, is being developed as a potential treatment for pantothenate kinase-associated neurodegeneration (“PKAN”). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include parkinsonism, dystonia, and other severe systemic manifestations. There are currently no viable treatment options for patients with PKAN.  RE-024 is a phosphopantothenate prodrug therapy that aims to restore levels of this key substrate in PKAN patients.  Certain ex-US health regulators have approved the initiation of dosing RE-024 in PKAN under physician-initiated studies in accordance with local regulations in their respective countries.   The Company filed a U.S. IND for RE-024 with the FDA in the first quarter of 2015 to support the commencement of a Company-sponsored Phase 1 study, which initiated in April 2015. RE-024 was granted orphan drug designation from the FDA on May 5, 2015 and was granted fast track designation on June 4, 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RE-034 is a synthetic hormone analog of the first 24 amino acids of the 39 amino acids contained in adrenocorticotropic hormone (“ACTH”) incorporated into a novel formulation developed by the Company.  RE-034 exhibits similar physiological actions as endogenous ACTH by binding to melanocortin receptors, resulting in its anti-inflammatory and immunomodulatory effects. The Company has successfully manufactured RE-034 at proof-of-concept scale using a novel formulation that allows modulation of the release of the active ingredient from the site of administration.  The Company intends to continue preclinical development of RE-034 to enable multiple strategic options.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Voucher Sale</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA granted Asklepion Pharmaceuticals, LLC (“Asklepion”) a Rare Pediatric Disease Priority Review Voucher ("Pediatric PRV"), awarded to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. A Pediatric PRV is transferable and provides the bearer with FDA priority review classification for a new drug application. The Pediatric PRV was transferred to Retrophin under the terms of the asset purchase agreement between the Company and Asklepion dated January 12, 2015 pursuant to which the Company acquired Cholbam</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 2, 2015, the Company sold and transferred the Pediatric PRV to Sanofi.  Pursuant to the Company’s agreement with Sanofi, the Company will receive </font><font style="font-family:inherit;font-size:10pt;">$245 million</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> was received upon closing, and </font><font style="font-family:inherit;font-size:10pt;">$47.5 million</font><font style="font-family:inherit;font-size:10pt;"> is due on each of the first and second anniversaries of the closing. The asset value of the Pediatric PRV recorded in the financial statements as of June 30, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$96.3 million</font><font style="font-family:inherit;font-size:10pt;">. In accordance with accounting principles generally accepted in the United States ("GAAP"), the Company recorded the future short term and long term payments at their present value of </font><font style="font-family:inherit;font-size:10pt;">$46.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$44.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, at the date of the sale. The incremental gain from the sale of the asset was approximately </font><font style="font-family:inherit;font-size:10pt;">$140.0 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended September 30, 2015, net of </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> in fees contractually due as part of the Cholbam</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> acquisition.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 11, 2015, the General Court of the European Union annulled the marketing authorization (“MA”) for Kolbam (bottled and branded name of Cholbam</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> in Europe) in recognition of the orphan market exclusivity afforded to Orphacol. This was the result of a lawsuit brought by a competitor product against the awarding of the MA for Kolbam by the EU Commission, citing similarities in the efficacy statements in a section of the labelling, and the competitor claimed circumvention of market exclusivity attached to Orphacol. The competitor product received its MA and orphan designation before Kolbam’s MA, which purportedly entitled it to 10 years of market exclusivity. The EU Court ruled in favor of the competitor, and Kolbam’s MA was withdrawn. The withdrawal of the MA was solely based on market exclusivity, and not for safety or efficacy reasons. At the time of the EU Court’s ruling, the product was launched in one EU country, France.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kolbam is currently available in Europe only through nationally approved Named Patient Programs.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 24, 2015, the European Committee for Medical Products for Human Use adopted an opinion recommending the Company be granted a MA for Kolbam. We anticipate a ruling from the EU Commission on the issuance of a new MA with revised labeling by the end of the year</font></div></div> |
